An open label phase II study evaluating effects of combining irinotecan (FOLFIRI) and bevacizumab (BV) plus erlotinib (ER) in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2017
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 Sep 2017 New trial record